

Table S1: Impact of donor type on the treatment outcome: comparing MSD vs. MUD

	MSD (n=18)	MUD group (n=10)	<i>P</i> value
2-year OS	61.6±12.6%	71.7%±14.4%	0.33
2-year EFS	57.8±12.4%	71.7%±14.4%	0.22
2-year NRM	12.9±8.9%	23.9%±14.4%	0.71
2-year CIR	26.1±13.3%	10.0%±9.5%	0.13
aGVHD			
II-IV aGVHD	25.6±9.9%	50.0%±15.8%	0.08
III-IV aGVHD	11.2±7.4%	30.0%±14.8%	0.18
cGVHD			
cGVHD	25.8±11.2%	58.3%±18.3%	0.13
moderate/severe cGVHD	0%	28.2%±17.1%	0.05
2-year GRFS	50.0±15.8%	37.8%±12.5%	0.82

MSD: Matched sibling donor; MUD: Matched unrelated donor; OS: Overall survival; EFS: Event-free survival; NRM: Non-relapsed mortality; CIR: Cumulative incidence of recurrence; aGVHD: Acute graft-versus-host disease; cGVHD: Chronic graft-versus-host disease; GRFS: GVHD-free, relapse-free survival

Table S2: Comparison of treatment outcome in patients with MSD: present vs. historical group

	Historical group	PT-Cy group	<i>P</i> value
2-year OS	60.1±11.9%	61.6±12.6%	0.76
2-year EFS	60.2±11.1%	57.8±12.4%	0.68
2-year NRM	10.0±9.5%	12.9±8.9%	0.12
2-year CIR	37.7±11.1%	26.1±13.3%	0.39
aGVHD			
II-IV aGVHD	26.3±10.1%	25.6±9.9%	0.75
III-IV aGVHD	9.38±6.1%	11.2%±7.4%	0.41
cGVHD			
cGVHD	58.4±14.4%	25.8±11.2%	0.52
moderate/severe cGVHD	20.0±10.3%	0%	0.12
2-year GRFS	42.1±11.3%	50.0±15.8%	0.72

MSD: Matched sibling donor; OS: Overall survival; EFS: Event-free survival; NRM: Non-relapsed mortality; CIR: Cumulative incidence of recurrence; aGVHD: Acute graft-versus-host disease; cGVHD: Chronic graft-versus-host disease; GRFS: GVHD-free, relapse-free survival

Table S3: Comparison of treatment outcome in patients with MUD: present vs. historical group

	Historical group	PT-Cy group	<i>P</i> value
2-year OS	57.8±9.3%	71.7±14.4%	0.34
2-year EFS	55.2±9.2%	71.7±14.4%	0.27
2-year NRM	19.6±7.6%	23.9±14.4%	0.88
2-year CIR	35.8±9.6%	10.0±9.5%	0.08
aGVHD			
II-IV aGVHD	50.0±15.8%	50.0±15.8%	0.98
III-IV aGVHD	23.6±7.6%	30.0±14.8%	0.14
cGVHD			
cGVHD	67.7±12.4%	58.3±18.3%	0.64
moderate/severe cGVHD	33.8±11.7%	28.2±17.1%	0.94
2-year GRFS	31.0±8.6%	37.8±12.5%	0.62

MUD: Matched unrelated donor; OS: Overall survival; EFS: Event-free survival; NRM: Non-relapsed mortality; CIR: Cumulative incidence of recurrence; aGVHD: Acute graft-versus-host disease; cGVHD: Chronic graft-versus-host disease; GRFS: GVHD-free, relapse-free survival

Table S4: Multivariate analysis of factors associated with overall survival

	RR	95% (CI)	<i>P</i> value
GVHD prophylaxis (PT-Cy vs. standard)	0.987	0.451~2.164	0.98
Sex	0.925	0.409~2.091	0.85
Age	0.545	0.245~1.209	0.14
Stage of disease (CR1 vs. PR/CR2 or beyond)	0.648	0.271~1.546	0.33
Donor (MSD vs. MUD/Haplo)	0.918	0.421~2.002	0.83

RR: Risk Ratio; CI: Confidence Interval; GVHD: Graft-versus-host disease; PT-Cy: Post-transplantation cyclophosphamide; CR: Complete remission; PR: Partial remission; MSD: Matched sibling donor; MUD: Matched unrelated donor; Haplo: Haplo-identical donor

Table S5: Multivariate analysis of factors associated with event-free survival

	RR	95% (CI)	<i>P</i> value
GVHD prophylaxis (PT-Cy vs. standard)	0.928	0.440~1.959	0.85
Sex	0.882	0.405~1.919	0.75
Age	0.311	0.271~1.486	0.33
Stage of disease (CR1 vs. PR/CR2 or beyond)	0.697	0.293~1.658	0.41
Donor (MSD vs. MUD/Haplo)	1.146	0.544~2.415	0.72

RR: Risk Ratio; CI: Confidence Interval; GVHD: Graft-versus-host disease; PT-Cy: Post-transplantation cyclophosphamide; CR: Complete remission; PR: Partial remission; MSD: Matched sibling donor; MUD: Matched unrelated donor; Haplo: Haplo-identical donor

Table S6: Multivariate analysis of factors associated with non-relapse mortality

	RR	95% (CI)	<i>P</i> value
GVHD prophylaxis (PT-Cy vs. standard)	1.880	0.581~6.079	0.29
Sex	0.817	0.230~2.905	0.76
Age	0.577	0.160~2.078	0.40
Stage of disease (CR1 vs. PR/CR2 or beyond)	2.452	0.310~19.378	0.40
Donor (MSD vs. MUD/Haplo)	0.714	0.208~2.451	0.59

RR: Risk Ratio; CI: Confidence Interval; GVHD: Graft-versus-host disease; PT-Cy: Post-transplantation cyclophosphamide; CR: Complete remission; PR: Partial remission; MSD: Matched sibling donor; MUD: Matched unrelated donor; Haplo: Haplo-identical donor

Table S7: Multivariate analysis of factors associated with relapse rate

	RR	95% (CI)	<i>P</i> value
GVHD prophylaxis (PT-Cy vs. standard)	0.533	0.193~1.469	0.22
Sex	1.089	0.408~2.909	0.86
Age	0.416	0.256~1.768	0.42
Stage of disease (CR1 vs. PR/CR2 or beyond)	0.177	0.501~1.366	0.18
Donor (MSD vs. MUD/Haplo)	0.535	0.534~3.348	0.54

RR: Risk Ratio; CI: Confidence Interval; GVHD: Graft-versus-host disease; PT-Cy: Post-transplantation cyclophosphamide; CR: Complete remission; PR: Partial remission; MSD: Matched sibling donor; MUD: Matched unrelated donor; Haplo: Haplo-identical donor